Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.61 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.42 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396380 | 0.80 | PIK3CD (0.62) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| Bromide SCHEMBL2398769 | 0.80 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| SCHEMBL48660 | 0.76 | PIK3CG (1.00) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| SCHEMBL48835 | 0.75 | PIK3CD (0.81) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| SCHEMBL12363422 | 0.74 | PIK3CD (0.80) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| SCHEMBL2395479 | 0.74 | PIK3CD (0.59) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| SCHEMBL2393804 | 0.74 | PIK3CD (0.67) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL49387 | 0.74 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| SCHEMBL48466 | 0.73 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| SCHEMBL1784761 | 0.73 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
| EP-1608647-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | Novartis AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004078754-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | PIK3CD 42/4885PIK3CG 49/4885PIK3CA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.